The purpose of the research was the identification of association of organs and systems damage in Sjogren’s syndrome with the presence of organ-specific and organ-nonspecific autoantibodies.
On the basis of complex examination of 21 patients with Sjogren’s syndrome (women age 53,5 ± 0,9 years old) and content determination of wide spectrum of organ-specific and organ-nonspecific autoantibodies we estimated the existence of association between presence of these autoantibodies and clinical manifestations of Sjogren’s syndrome. The received results demonstrate the relationship between the expressiveness of inflammatory manifestations and the content of antibodies to DNA. The expressiveness of salivary glands injuries is associated with content of autoantibodies to salivary glands. The presence of associated diseases is also associated with existence of particular autoantibodies. As in all examined patients with Sjogren’s syndrome was present the digestive tract pathology, it can be assumed that changes in digestive tract wall lead to damage of immune system structures and polyclonal uncontrollable activation of antibodies production.

Sjogren’s syndrome, organ-specific autoantibodies, organ-nonspecific autoantibodies, clinical features

Vasilev V.I. Klinika, diagnostika i differentsialnaya diagnostika bolezni Shegrena [Clinic, diagnostics and differential diagnosis of Sjogren’s syndrome ]. Russkiy meditsinskiy zhurnal. Revmatologiya, 2008; 10(16): 638-649. ( in Russian)

Lopatina I.A., Lopatkina T.N., Tanaschuk E.L., Arion E.A. Variantnaya forma porazheniya pecheni: autoimmunnyiy gepatit – pervichnyiy biliarnyiy tsirroz pecheni pri bolezni Shegrena [Alternative form of damage of a liver: autoimmune hepatitis – primary biliary cirrhosis at Sjogren's syndrome.]. Klinicheskaya meditsina, 2013; 1: 66-70. (in Russian)

A.V.Gordeev, E.A.Galushko, E.L.Nasonov Kontseptsiya polimorbidnosti v revmatologicheskoy praktike [The concept of a polimorbidity in rheumatologic practice]. Nauchno-prakticheskaya revmatologiya. 2014; 4: 362-365. (in Russian)

Selifanova E.I., Simonova M.V., Razumova S.I., Bulgakov V.S Diagnostika bolezni i sindroma Shegrena v usloviyah stomatologicheskoy polikliniki [Diagnostics of Sjogren's syndrome in the conditions of dental policlinic.]. Rossiyskiy stomatologicheskiy zhurnal, 2016; 20(4): .218-220. ( in Russian)

Nikitin N.M., Afanasev I.A., Rebrov A.P. Komorbidnost u bolnyih revmatoidnyim artritom [Komorbidity at patients with rheumatoid arthritis.]. Nauchno-prakticheskaya revmatologiya. 2015; 2: 149 - 154. ( in Russian)

Panchovska M.S., Sheytanov Y.I., Stoilov R.M., Martinova F.G., Nikolov K.G. Pervichnyiy sindrom Shegrena i bazedova bolezn (semeynyiy sluchay )[ Primary Sjogren’s syndrome and bazedov disease (family case)]. Nauchno-prakticheskaya revmatologiya. 2001; 1: 71-72. ( in Russian)

Vasilev V.I., Simonova M.V., Safonova T.N., Logvinenko O.A. Sovremennyie podhodyi k ispolzovaniyu glyukokortikoidnyih i tsitotoksicheskih preparatov pri bolezni Shegrena [Modern approaches to use of glucocorticoid and cytotoxic medicines at Sjogren's syndrome.]. Sovremennaya revmatologiya. 2008; 2: 39-56. ( in Russian)

Kuvardin E.S., Grigoreva N.I., Maslyanskiy A.L., Hohlov D.S., Behtereva I.A., Krivolapov Yu.D. Cpektr kletochnyih subpopulyatsiy limfotsitarnyih fokusov maloy slyunnoy zhelezyi pri bolezni Shegrena kak dopolnitelnogo kriteriya diagnostiki [Range of cellular subpopulations of lymphocytic focuses of small salivary gland at Sjogren's syndrome as additional criterion of diagnostics]. Nauchno-prakticheskaya revmatologiya 2018; 56 (suppl. 3): 21-22. ( in Russian)

Shornikova N.S., Vasilev V.I., Smirnov A.V. Porazhenie sustavov pri bolezni Shegrena [Damage of joints at Sjogren's syndrome]. Nauchno-prakticheskaya revmatologiya. 2002; 1: 13( in Russian)

American college of rheumatology classification criteria for Sjogren’s syndrome a data-driven, expert consensus approach in the SICCA cohort. Shiboski S., Shiboski C., Criswell L. et al. Arthritis Care res. 2012; 64 (4): 475-487.

Csepregi A., Szodaray P., Zeher M. Do antibodies predict autoimmune liver disease in primary Sjogren’s syndrome? Data of 180 patients upon a 5years follow up. Scand. J. Immunol. 2002; 56: 623-629.

Diagnostic accuracy of anti-alpha-fodrin antibodies for primary Sjogren’s syndrome Quin Q., Wang H., Huang YL, Li H, Zhang WW, Zhang LR, He LL, Zhao DB, Deng AM Mod. Rheumatol. 2014; 24(5): 793-797.

EULAR recommendation for the management of rheumatoid arthritis with syntetic and biologikal disease-modifying antirheumatic drugs. Smolen J.S., Landewe R., Breedveld F.C. et al. Ann. Rheum. Diseases. 2013; 73: 492 - 509.

Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissiu disease. Helenius L.M., Hietanen J.H., Helenius I. et al. Ann. Rheum. Dis. 2001; 60: 744-749.

Goldblatt F., O’Neil S.C. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013; 382: 797-807.

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. Giacomelli R, Afeltra A, Alunno A et al. Autoimmune res. 2017; sept 16(9): 911- 924.

Jiunn-Hong Kang, Herng-Ching Lin Comorbidites in patient with primary Sjogren’s syndrom a registry-based case-control study. J.Rheumatol. 2010; 37(16): 1188-1194.

Kassan S.S., Moutsopoulos H.M. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch.Intern.Med. 2004; 164: 1275–1284.

Mattews S.A., Kurien B.T., Scofield R.H. Oral manifestation of Sjogren’s syndrome. J.Dental Research. 2008; 87(4): 308-318.

Prelevance of xerostomia in population-based samples: a systematic rewiev. Orellana M.F., Lagraviere M.O., Boychuk D.G. et al. J.Public.Health.Dent. 2006; 66(2): 152-158.

Ramos–Casals M., Tzioufas A., Font J. Primary Sjogren’s syndrome: new clinical and therapeutic concepts. Ann.Rheum.Dis. 2005; 64, 1: 347 – 354 22.Rosseir V., Bart P.A., Spertini F. Sjogren’s syndrome: a new approach to treatment. Rev. Med. Sci. 2012; 18; 8(337): 843 -847.

Reviewing primary Sjogren’s syndrome: beyond the dryness. From pathophysiology to diagnosis and treatment. Both T., Dalm V.A., van Hagen P.M. et al. Int.J.Med. Sci. 2017; 14(3): 191-200.